SJ1008030 TFA

Cat. No.:	HY-147330A
CAS No.:	2863634-97-1
Molecular Formula:	$C_{44}H_{44}F_3N_{13}O_9S$
Molecular Weight:	987.96
Target:	PROTACs; JAK
Pathway:	PROTAC; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Storage:	-20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



BIOLOGICAL ACTIVITY

Description	SJ1008030 (compound 8) TFA is a JAK2 PROTAC which selectively degrades JAK2. SJ1008030 TFA inhibits MHH–CALL-4 cell growth with an IC_{50} of 5.4 nM. SJ1008030 TFA can be used for the research of leukemia[1].
IC_{50} & Target	JAK2
In Vitro	SJ1008030 (compound 8) (72 h) TFA shows activity in CRLF2r cell lines (MHH-CALL-4), with an IC_{50} of 5.4 nM[1]. SJ1008030 (0-4.3 μM; 72 h) TFA degrades JAKs, GSPT1, and IKZF1 in a dose-dependent manner in MHH–CALL-4 cells[1]. SJ1008030 (0-10 μM; 24h) TFA dose-dependently degrades JAK2 and GSPT1 protein in xenograft bone marrow SJBALL021415 cells, indicating the inhibition of JAK-STAT signaling pathway[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Chang Y, et al. Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia. Blood. 2021 Dec 9;138(23):2313-2326.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA